Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.

× No keyword cloud information.

4 in total

1. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors: Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal: N Engl J Med Date: 2006-06-15 Impact factor: 91.245

2. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

Authors: Maria-Theresa Krauth; Susanne Herndlhofer; Maria-Theresa Schmook; Gerlinde Mitterbauer-Hohendanner; Ernst Schlögl; Peter Valent
Journal: Haematologica Date: 2010-10-07 Impact factor: 9.941

3. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Authors: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Charles Koller; Gautam Borthakur; Brenda Walker; Weiqiang Zhao; Jianqin Shan; Hagop Kantarjian
Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544

Review 4. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

Authors: David Masiello; Gerry Gorospe; Allen S Yang
Journal: J Hematol Oncol Date: 2009-11-12 Impact factor: 17.388

4 in total

7 in total

1. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.

Authors: Peter Valent
Journal: Haematologica Date: 2011-10 Impact factor: 9.941

Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.

1. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

2. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

3. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Review 4. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

1. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.

2. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

Review 3. Dasatinib-induced pulmonary arterial hypertension.

Review 4. Case study-based systematic review of literature on lymphoma-associated cardiac tamponade.

5. Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia.

Review 6. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

7. COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey